Around the world, one in every four people is using social media. Whether they are sharing a funny cat video, advice on dating, or their personal experiences living with a chronic illness, there are nearly two billion people connecting with one another through Facebook, Twitter, Instagram, LinkedIn, and other social platforms, forever transforming the way humans communicate. This social media ecosystem also is ushering in a “digital health revolution.” Whether through their desktops, laptops, or mobile devices, people seeking medical and wellness information first check with their social networks.
Pharmaceutical companies have started entering the social media waters – — most with one toe in first. Given the increasing dependence on the digital world, social media is a natural touch point for companies to connect with the patients and healthcare providers (HCPs) they serve. Becoming truly social has not been an easy proposition for a conservative industry. But we have reached a tipping point, where social interaction is becoming critically important for the industry, and one that is blowing the lid off of the traditional way of communicating with stakeholders.
In the old paradigm, a pharmaceutical brand issues an advertisement that directs patients and HCPs to a website where they are provided one-sided information and an overall static experience. Patients are then directed to “talk to your doctor,” and that is where the interaction ends. Within the new social paradigm, patients, HCPs and pharmaceutical companies can have real conversations about the topics that are important to all of them. Patients also can access information and answers to their questions much faster, thereby making their path to help shorter.
Pharmaceutical companies have an opportunity to interact with patients and HCPs in a more meaningful way through social media. At Ogilvy, we are helping our pharmaceutical clients navigate this new paradigm and create unbranded social networks that offer patients who have similar life experiences – — whether that is quitting smoking or managing cancer – — a safe and comfortable environment to listen, learn, and share. We believe these networks offer unique value to the industry, allowing companies to provide patients with a support system where such a community may not otherwise exist.
Social networks resolve the limitations of both time and geography that are inherent with in-person support groups. They allow people to access information targeted to their concerns and conversations with global peers at any hour from the comfort and privacy of their own couch. Social networks also empower patients to initiate and direct conversations, interacting in a way that is meaningful to them. These networks are already forming, and we believe it is vital for industry to take the lead, to serve as the connector of those conversations, and to interact so that patients are assured they are receiving the best quality and most credible information.
The social media world has clearly shifted communication patterns and habits. Pharmaceutical companies can no longer afford to remain disconnected. Social interaction and sharing will continue whether or not the industry gets more involved. By taking a more active role within these patient communities, a pharmaceutical company allows its own voice and expertise to be heard, provides its stakeholders with real value, and, equally important, ensures that competitors aren’t the only ones creating meaningful interactions and relationships with consumers.
CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at email@example.com.
Please allow 24 hours for response.